TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28569047
Drug: Alglucerase/imiglucerase enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alglucerase/imiglucerase enzyme replacement therapy (ERT)
Study: 28569206
Drug: 3-direct-acting-antiviral (DAA)
Normalized name: DIRECT BLUE 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-direct-acting-antiviral (DAA) regimen combining simeprevir (SMV), TMC647055/ritonavir (RTV), and JNJ-56914845
Study: 28570742
Drug: Conformal radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conformal radiation therapy (RT) individualized to a fixed risk of RT-induced lung toxicity (RILT) and adaptively escalated to the residual tumor defined on midtreatment FDG-PET up to a total dose of 86 Gy in 30 daily fractions, with concurrent weekly carboplatin plus paclitaxel.
Study: 28571635
Drug: β-blockers in
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: β-blockers in ST-segment elevation myocardial infarction
Study: 28571635
Drug: β-blockers in
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: β-blockers in non-ST-segment elevation myocardial infarction
Study: 28571635
Drug: No β-blockers
Approvals — FDA: no, EMA: no, PMDA: no
Description: No β-blockers (Control)
Study: 28574652
Drug: Rivaroxaban 20
Normalized name: rivaroxaban 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 20 mg administered once daily
Study: 28575278
Drug: 0.5 million
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 million IU (MIU) of nebulized colistin methanesulfonate (CMS) administered every 8 hours as 30-minute nebulizations
Study: 28575299
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) treatment during childhood
Study: 28575323
Drug: darunavir/ritonavir (800/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: darunavir/ritonavir (800/100 mg) once-daily regimen
Study: 28575323
Drug: darunavir/cobicistat (800/150
Approvals — FDA: no, EMA: no, PMDA: no
Description: darunavir/cobicistat (800/150 mg) once-daily regimen
Study: 28575523
Drug: Fidaxomicin (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fidaxomicin (16 mg/kg per day, up to 200 mg, twice daily for 10 days)
Study: 28576754
Drug: Hydroxyurea treatment
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea treatment starting at approximately 20 mg/kg/day for 6 months, escalating to maximum tolerated dose (MTD) thereafter.
Study: 28576754
Drug: Hydroxyurea at
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea at maximum tolerated dose (MTD).
Study: 28577353
Drug: Simeprevir 150
Normalized name: simeprevir 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simeprevir 150 mg once daily plus Peginterferon α-2a/Ribavirin for 12 weeks followed by Peginterferon α-2a/Ribavirin for 12 or 36 weeks (response-guided therapy) or 36 weeks fixed (non-responders).
Study: 28577957
Drug: Osimertinib (AZD9291)
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Osimertinib (AZD9291) treatment
Study: 28578302
Drug: Antibiotics (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (administered per standard of care for 5 days)
Study: 28578302
Drug: Omeprazole (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (administered over 14 days)
Study: 28578535
Drug: Increased daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased daily water intake over 6 weeks
Study: 28579823
Drug: Immediate-release (IR)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release (IR) opioids (hydrocodone-acetaminophen and oxycodone-acetaminophen)
Study: 28579823
Drug: Immediate-release (IR)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release (IR) opioids
Study: 28580793
Drug: Lanreotide plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide plus Metformin (MET)
Study: 28580917
Drug: Fragment antigen-binding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fragment antigen-binding domains (Fabs) isolated from human monoclonal antibodies targeting NHBA
Study: 28581396
Drug: F-18 fluorodeoxyglucose
Normalized name: Fludeoxyglucose F-18
DrugBank: Fludeoxyglucose (18F) (DB09502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: F-18 fluorodeoxyglucose (FDG) PET during chemoradiation therapy (CRT)
Study: 28581691
Drug: Recombinant factor
Normalized name: Recombinant factor IX
DrugBank: Coagulation Factor IX (Recombinant) (DB00100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant factor XIII-A (rFXIII) prophylaxis, 35 IU/kg once monthly
Study: 28582240
Drug: Tablet-based application
Normalized name: BAKING POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-based application (EPIC Wheels) with two in-person sessions and four weeks of independent home training
Study: 28582240
Drug: Tablet-based application
Normalized name: BAKING POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-based application (EPIC Wheels) with expert trainer monitoring
Study: 28582240
Drug: Tablet-based application
Normalized name: BAKING POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-based application (EPIC Wheels) with video instruction and interactive training games
Study: 28582240
Drug: Tablet-based application
Normalized name: BAKING POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-based application (EPIC Wheels) with standardized configuration for Wi-Fi devices
Study: 28583131
Drug: Store features
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Store features with health promoting characteristics (e.g., fruit/vegetable shelf space, Healthy Food Supply Score)
Study: 28583305
Drug: DTaP5-IPV-HB-Hib vaccine
Normalized name: poliovirus vaccine inactivated, type 1 (Mahoney)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP5-IPV-HB-Hib vaccine administered at 2 and 6 months of age, DTaP5-IPV-Hib at 4 months, MCC vaccine at 2 and 4 months, and routine rotavirus and pneumococcal vaccination.
Study: 28583305
Drug: Mixed schedule
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed schedule including DTaP5-IPV-HB-Hib and MCC vaccine.
Study: 28583305
Drug: Mixed schedule
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed schedule with hexavalent vaccine and MCC vaccine.
Study: 28583305
Drug: Hexavalent vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexavalent vaccine co-administered with MCC vaccine.
Study: 28583305
Drug: Study vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study vaccine doses.
Study: 28583617
Drug: Implantable IV
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implantable IV infusion system for treprostinil
Study: 28584140
Drug: CRS3123 (Methionyl-tRNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRS3123 (Methionyl-tRNA Synthetase Inhibitor)
Study: 28584142
Drug: Micafungin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micafungin treatment
Study: 28588421
Drug: Novel product
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel product containing glycolic acid, sodium bicarbonate, glycerin, and other buffering agents, applied once before irrigation with warm water
Study: 28588426
Drug: Ramadan fasting
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramadan fasting (RF) with clopidogrel at a maintenance dose of 75 mg
Study: 28588426
Drug: Clopidogrel at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel at a maintenance dose of 75 mg without Ramadan fasting
Study: 28588982
Drug: RUTF-L
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RUTF-L
Study: 28588992
Drug: mRDTs (malaria
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRDTs (malaria rapid diagnostic tests) introduced in drug shops
Study: 28589492
Drug: LY2874455 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2874455 at 16 mg BID (RP2D)
Study: 28592319
Drug: Daily 360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily 360 μg of menaquinone-7 for 4 weeks
Study: 28592387
Drug: Dabrafenib plus
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dabrafenib plus trametinib (oral dabrafenib 150 mg twice per day and oral trametinib 2 mg once per day)
Study: 28592434
Drug: Rosuvastatin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin treatment for 2 years, starting at 5 mg once daily, uptitrated to 10 mg (age 6-<10 years) or 20 mg (age 10-<18 years).
Study: 28592616
Drug: Panitumumab (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panitumumab (6 mg/kg, administered intravenously every 2 weeks)
Study: 28592615
Drug: Cobimetinib and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cobimetinib and duligotuzumab combination
Study: 28592624
Drug: Pemetrexed 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 150 mg/m2 via 8-hour intravenous infusion followed by gemcitabine
Study: 28593789
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers
Study: 28594762
Drug: Shared decision-making
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shared decision-making intervention using a tablet computer-based decision aid for opioid prescribing after cesarean delivery.
Study: 28594762
Drug: Standard prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard prescription of 40 tablets of 5 mg oxycodone.
Study: 28595189
Drug: Oral BCAA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral BCAA (30.7 ± 1.1 g)
Study: 28595189
Drug: IV BCAA
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV BCAA (30.7 ± 1.1 g)
Study: 28595339
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy (CRT-D) responders
Study: 28595616
Drug: Oral ridaforolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ridaforolimus 30 mg daily for 5 consecutive days per week combined with intravenous paclitaxel 175 mg/m2
Study: 28596794
Drug: Herbal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal therapy (5 shenwu capsules/administration, 3 times/day)
Study: 28596794
Drug: Donepezil (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (placebo identical to donepezil tablets)
Study: 28596794
Drug: Herbal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal therapy
Study: 28597842
Drug: Lacosamide (initiated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacosamide (initiated at 100 mg/day, uptitrated to 200, 300, or 400 mg/day over 12 weeks)
Study: 28598554
Drug: Biological brothers
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biological brothers
Study: 28600132
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin 1·8 mg/kg once every 3 weeks for up to 16 cycles
Study: 28600132
Drug: Physician's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician's choice (oral methotrexate 5-50 mg once per week or oral bexarotene 300 mg/m2)
Study: 28601434
Drug: Moroctocog alfa
Normalized name: MOROCTOCOG ALFA
DrugBank: Moroctocog alfa (DB13999)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Moroctocog alfa (AF-CC) 50 IU/kg IV
Study: 28601641
Drug: Icatibant (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icatibant (0.4 mg/kg; maximum 30 mg)
Study: 28601826
Drug: Metformin and
Normalized name: metformin and acarbose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin and chloroquine
Study: 28602587
Drug: Epidermal cell
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidermal cell suspension spray
Study: 28602587
Drug: Noncultured keratinocyte
Normalized name: Foreskin keratinocyte (neonatal)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noncultured keratinocyte suspension
Study: 28602585
Drug: Fedratinib 400
Normalized name: FEDRATINIB
DrugBank: Fedratinib (DB12500)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fedratinib 400 mg once per day for six consecutive 28-day cycles
Study: 28606999
Drug: Early dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early dual antiplatelet treatment
Study: 28607547
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg + Domperidone 30 mg (group 1)
Study: 28607547
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg (group 2)
Study: 28607691
Drug: MIS416 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIS416 administered once weekly for four weeks, then once weekly for up to 12 weeks at a dose of 500 µg/week.
Study: 28607743
Drug: Subcutaneous peginterferon
Normalized name: peginterferon alfa-2a Injection [Pegasys]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous peginterferon beta-1a every 2 weeks
Study: 28608617
Drug: Canagliflozin 100
Normalized name: canagliflozin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin 100 mg added to teneligliptin 20 mg orally once daily for 52 weeks
Study: 28610605
Drug: 12 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 weeks of directly observed peg-interferon alfa-2b (PEG-IFN) and self-administered ribavirin
Study: 28610605
Drug: 24 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24 weeks of directly observed peg-interferon alfa-2b (PEG-IFN) and self-administered ribavirin
Study: 28610605
Drug: 12 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 weeks of therapy vs 24 weeks
Study: 28611037
Drug: Empagliflozin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin (25 mg/day) for 2 weeks
Study: 28611126
Drug: Left Ventricular
Normalized name: DRESSING,VENTRICULAR ASSIST DEVICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Left Ventricular Assist Device (LVAD) therapy
Study: 28611778
Drug: Peg-Interferon Lambda
Normalized name: PEG-Interferon alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peg-Interferon Lambda Treatment
Study: 28612237
Drug: No L-thyroxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: No L-thyroxine
Study: 28613220
Drug: Intravitreal injections
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injections of Lucentis
Study: 28614154
Drug: High-dose intralesional
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intralesional ziv-aflibercept (0.1 mL to 0.3 mL, 2.5 mg to 7.5 mg)
Study: 28614154
Drug: High-dose intralesional
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intralesional ziv-aflibercept
Study: 28614995
Drug: Tobramycin inhalation
Normalized name: Tobramycin Inhalation Powder
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin inhalation powder (TIP) via T-326 inhaler
Study: 28614995
Drug: Tobramycin inhalation
Normalized name: Tobramycin Inhalation Powder
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin inhalation solution (TIS) via nebulizer
Study: 28614995
Drug: Tobramycin inhalation
Normalized name: Tobramycin Inhalation Powder
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin inhalation solution (TIS) and Colistimethate sodium (COLI) via nebulizers
Study: 28615265
Drug: Nutritional intake
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional intake from food and supplements; specific details on dosage and duration not available.
Study: 28615279
Drug: MOAT (Medicines
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOAT (Medicines Optimisation Assessment Tool)
Study: 28615304
Drug: Ibuprofen exposure
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen exposure
Study: 28615304
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no ibuprofen exposure)
Study: 28616853
Drug: Ceramide dominant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceramide dominant therapeutic moisturizer applied twice daily for 12 weeks
Study: 28618864
Drug: Bacteroidetes/Firmicutes-ratio and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacteroidetes/Firmicutes-ratio and peripheral insulin sensitivity in men
Study: 28618864
Drug: Bacteroidetes/Firmicutes-ratio and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacteroidetes/Firmicutes-ratio and peripheral insulin sensitivity after adjustment
Study: 28618864
Drug: Bacteroidetes/Firmicutes-ratio and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacteroidetes/Firmicutes-ratio and hepatic insulin sensitivity
Study: 28619116
Drug: Individual low-threshold
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual low-threshold physical activity intervention with counseling from a personal coach during and 3 months after chemotherapy
Study: 28620382
Drug: CSF-470 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSF-470 vaccine plus Bacillus Calmette-Guerin (BCG) and recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF)
Study: 28620382
Drug: Medium-dose Interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose Interferon Alpha 2B
Study: 28620471
Drug: Plant sterol-enriched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterol-enriched spread (3 g/d)
Study: 28622099
Drug: Concurrent use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent use of energy drinks with alcohol
Study: 28622099
Drug: Energy drinks
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy drinks without concurrent alcohol use
Study: 28622450
Drug: Oesophageal Capsule
Normalized name: Cellspan Esophageal Implant
DrugBank: Cellspan Esophageal Implant (DB18688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oesophageal Capsule Endoscopy (ECE)
Study: 28622454
Drug: Tocilizumab (intravenous)
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab (intravenous)
Study: 28622959
Drug: Lenalidomide 25
Normalized name: lenalidomide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 25 mg on days 1 to 21 and panobinostat 15 mg TIW for phase II
Study: 28622959
Drug: Lenalidomide 25
Normalized name: lenalidomide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 25 mg and panobinostat 20 mg
Study: 28622959
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of panobinostat and lenalidomide
Study: 28623902
Drug: Optimal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal treatment as specified in international guidelines
Study: 28623988
Drug: Rivaroxaban (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (10 mg/d) for EHIT prophylaxis
Study: 28623995
Drug: Current treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current treatment approaches for SVT (including oral and injectable anticoagulants, pain medication, compression therapy, and no treatment)
Study: 28625777
Drug: Subcutaneous trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous trastuzumab (Herceptin) 600 mg fixed-dose every 3 weeks for 18 cycles
Study: 28629395
Drug: Tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil fumarate (TDF) therapy initiated based on EASL criteria; 74 patients (24.7%) started TDF therapy, 46 (62.2%) had cirrhosis.
Study: 28629466
Drug: Stromal vascular
Normalized name: Autologous stromal vascular fraction from adipose tissue
DrugBank: Autologous adipose-derived stromal vascular fraction cells (DB18679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stromal vascular fraction (SVF) and platelet rich plasma (PRP) intra-articular injection
Study: 28629584
Drug: Met the
Approvals — FDA: no, EMA: no, PMDA: no
Description: Met the vitamin D estimated average requirement (EAR) intake (10 μg/d)
Study: 28629584
Drug: Sufficient serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufficient serum 25-hydroxyvitamin D (25(OH)D) (≥50 nmol/L)
Study: 28629584
Drug: Serum levels
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum levels at risk for inadequacy or deficiency (<50 nmol/L)
Study: 28630120
Drug: TPO agonists
Normalized name: Tpoxx
DrugBank: Tecovirimat (DB12020)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: TPO agonists
Study: 28630121
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human thrombopoietin (rhTPO) therapy
Study: 28630212
Drug: Stereotactic Body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic Body Radiation Therapy (SBRT) combined with Cytoreductive Nephrectomy
Study: 28630876
Drug: SIB-IMRT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIB-IMRT with doses of 69Gy, 75Gy, and 81Gy in 30 fractions to the internal gross tumor volume (iGTV)
Study: 28630876
Drug: Standard IMRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard IMRT plans prescribed a dose of 60Gy to the planning tumor volume (PTV)
Study: 28632462
Drug: Group Integrated
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Integrated Cognitive-Behavioral Therapy (ICBT)
Study: 28633365
Drug: Copanlisib administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copanlisib administered intravenously on days 1, 8, and 15 of a 28-day cycle
Study: 28634491
Drug: Daily growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily growth hormone treatment (group A, 16 patients)
Study: 28634491
Drug: Three-times-weekly growth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-times-weekly growth hormone treatment (group B, 16 patients)